Eli Lilly and Company — News

US stock market is entering August against a turbulent backdrop, featuring continued Iran-driven volatility in oil prices and an ongoing earnings season. Plus, investors are still processing the recent Fed meeting where new chairman Kevin Warsh held benchmark rates steady.

invezz.com - 2026-08-03 23:16:07

Eli Lilly said on Monday it would allow a limited number of patients ​to have early access to its experimental obesity drug, ‌retatrutide, before its U.S. FDA approval.

reuters.com - 2026-08-03 18:30:56

Stock futures are pointing to a higher open to kick off August trading as investors look ahead to a packed week of earnings reports; oil prices are tumbling after the U.S. paused strikes on Iran over the weekend; SpaceX is due to reports earnings for the first time this week, headlining a busy week of corporate results; Palantir is scheduled to release its earnings report after the closing bell today; and shares of AstraZeneca and Bristol-Myers Squibb are moving sharply following a report that the pharmaceutical giants have discussed a potential merger. Here's what you need to know today.

investopedia.com - 2026-08-03 08:10:53

INDIANAPOLIS, Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation, as determined by an FDA-approved test. Olomorasib is an investigational, potent and highly selective next-generation inhibitor of KRAS G12C.

prnewswire.com - 2026-08-03 07:45:00

First National Bank of Mount Dora Trust Investment Services trimmed its position in Eli Lilly and Company (NYSE: LLY) by 21.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,440 shares of the company's stock after selling

defenseworld.net - 2026-08-03 04:17:56

Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit ​warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now they may have reason for hope.

reuters.com - 2026-08-03 01:02:58

In another heavy earnings week, we'll also see reports from McDonald's, Disney, Uber, Devon Energy, and more.

barrons.com - 2026-08-02 14:00:00

Abbott Laboratories maintains a diversified business model spanning diagnostics, medical devices, and nutrition products. Eli Lilly is experiencing rapid growth driven by its dominant presence in the cardiometabolic treatment market.

fool.com - 2026-08-02 07:55:34

Axiom Investment Management LLC acquired a new stake in Eli Lilly and Company (NYSE: LLY) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,411 shares of the company's stock, valued at approximately $1,297,000. Eli Lilly and Company

defenseworld.net - 2026-08-01 03:49:53

Novo Nordisk (NYSE: NVO | NVO Price Prediction) and Eli Lilly (NYSE: LLY) both posted Q1 FY2026 results this spring, and the gap between them keeps widening.

247wallst.com - 2026-07-31 13:30:12

Both companies are giants in diabetes and obesity treatments. Lately, Eli Lilly has moved ahead in the obesity segment.

fool.com - 2026-07-31 13:30:00

Wegovy and Zepbound makers Novo Nordisk and Eli Lilly faced selling pressure on Friday.

investors.com - 2026-07-31 11:51:22

$30.7 billion. That's how much was cut from Novo Nordisk's market capitalization as of Friday's share price, lowering from $229.2 billion to $198.5 billion, marking a nearly 69% decline since hitting an all-time high of $635.7 billion in June 2024.

forbes.com - 2026-07-31 11:15:09

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

zacks.com - 2026-07-31 10:16:17

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

zacks.com - 2026-07-31 10:01:34

IBD's Alexis Garcia and Ed Carson preview key upcoming earnings reports from Eli Lilly, Sandisk and SpaceX. Check out our daily newsletter!

youtube.com - 2026-07-31 07:00:06

BankChampaign National Association acquired a new position in Eli Lilly and Company (NYSE: LLY) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,121 shares of the company's stock, valued at approximately $1,031,000. Eli Lilly and Company accounts for approximately 1.0% of

defenseworld.net - 2026-07-31 04:03:58

Eli Lilly (LLY) and contract manufacturer Resilience will invest $750 million to expand pharmaceutical production in the Cincinnati region, adding Lilly's KwikP

gurufocus.com - 2026-07-30 11:19:00

� 2025 Benzinga.com. Benzinga does not provide investment advice.

benzinga.com - 2026-07-30 10:15:01

Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million to expand pharmaceutical manufacturing ​capacity in the U.S. and strengthen the domestic ‌medicine supply chain, Resilience said on Thursday.

reuters.com - 2026-07-30 08:58:45

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Astera Labs, Inc. (NASDAQ:ALAB) is a buy.

benzinga.com - 2026-07-30 08:15:22

The benchmark S&P 500 index has spent the summer coiled in a tight range just below its “short-term moving averages,” currently down over 3% from its June high. Beneath this surface-level stillness, an aggressive sector rotation is underway across the US stock market.

invezz.com - 2026-07-29 23:05:53

But is that performance sustainable?

fool.com - 2026-07-29 17:00:00

Next week keeps up the earnings barrage, a heavy dose of earnings from some of the market's largest companies, led by pharma giant Eli Lilly (LLY) and industrial bellwether Caterpillar (CAT).

schaeffersresearch.com - 2026-07-29 15:27:35

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-07-29 11:01:27

Eli Lilly is purchasing a psychedelic drug developer biotech, AtaiBeckley. That'll build out its mental health portfolio substantially.

fool.com - 2026-07-29 08:06:00

Amgen wants a slice of the weight loss drug market. Its candidate for capturing that market share might not be up to the task.

fool.com - 2026-07-29 07:30:00

Eli Lilly currently displays stronger upward momentum in top-line growth, whereas Johnson & Johnson maintains a higher but flatter overall baseline. Over roughly the last eight quarters, the two companies experienced diverging patterns, with Johnson & Johnson staying mostly stable quarter over quarter and Eli Lilly posting consistent sequential increases.

fool.com - 2026-07-29 07:24:01

One of Cathie Wood's funds just sold some AtaiBeckley shares. It also bought some Compass Pathways shares.

fool.com - 2026-07-29 05:00:00

Eli Lilly (LLY) closed the most recent trading day at $1, moving +2.09% from the previous trading session.

zacks.com - 2026-07-28 18:45:53

As AI-related stocks weaken, investors are rotating into other sectors, such as energy and health care.

investors.com - 2026-07-25 08:00:28

Eli Lilly (NYSE:LLY | LLY Price Prediction) has accelerated despite its $1 trillion scale.

247wallst.com - 2026-07-24 13:30:36

Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.

zacks.com - 2026-07-24 11:16:23

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.

barrons.com - 2026-07-24 09:09:00

Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.

wsj.com - 2026-07-24 05:48:00

Novo Nordisk said on Friday it is seeking a preliminary U.S. ​court injunction to immediately block obesity ‌and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry ​between the two groups.

reuters.com - 2026-07-24 04:41:44

There are plenty of reasons to love these companies.

fool.com - 2026-07-24 00:30:00

Eli Lilly & Co.'s next-generation weight-loss shot retatrutide didn't increase overall heart risk in a new study, helping dispel concerns over its potential. The company plans to file for US Food and Drug Administration approval early next year, later than investors hoped, due to the complexity of the approval pathway.

youtube.com - 2026-07-23 19:25:34

Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.

investors.com - 2026-07-23 13:38:21

Analysts have suggested retatrutide could become a blockbuster weight loss drug if approved. In January, TD Cowen analysts estimated retatrutide could generate $3.8 billion in sales in 2030, while GlobalData forecasts sales of $15.6 billion by 2031.

forbes.com - 2026-07-23 10:15:09

FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.

fool.com - 2026-07-23 08:15:25

Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.

wsj.com - 2026-07-23 06:48:00

Eli Lilly ‌on Thursday said two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit an application to the U.S. Food and Drug Administration in ​the first quarter of next year.

reuters.com - 2026-07-23 06:47:04

Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials.  The drug delivered significant weight loss and improvements in a key measure of blood sugar levels in adults with obesity and either Type 2 diabetes or established cardiovascular disease.

cnbc.com - 2026-07-23 06:45:02

In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some of its most serious complications: type 2 diabetes and established cardiovascular disease.

prnewswire.com - 2026-07-23 06:45:00

Seagate Technology shares continued to advance as demand for high-capacity storage tied to AI data-center buildouts supported further positive earnings revisions. On balance, the Fund's artificial intelligence positioning was a net positive contributor to relative performance during the quarter. We added the Humana position on the view that earnings are at a cyclical trough, with MA margins currently depressed, in some cases negative, as elevated medical cost trends have outpaced premium growth across the industry.

seekingalpha.com - 2026-07-22 12:35:00

The polite duopoly running the modern weight-loss drug boom just filed for divorce, and the market voted before the ink dried.

247wallst.com - 2026-07-22 12:25:21

INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

prnewswire.com - 2026-07-22 10:00:00

PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.

fool.com - 2026-07-22 06:45:33

President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.

finbold.com - 2026-07-22 06:31:14